Cybin CEO to Speak at Psychedelic Science 2025 Conference on Advancing Mental Health Treatments

Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) has announced that its CEO, Doug Drysdale, is set to speak at the Psychedelic Science 2025 Conference in Denver, marking a significant moment for the company and the psychedelic therapeutics industry. Drysdale will participate in a panel titled 'The Home Stretch: Pivotal Trials and Preparing for Launch' on June 19, focusing on the critical phase of clinical trials and the preparation for bringing new treatments to market. His participation underscores Cybin's commitment to pioneering next-generation mental health treatments through innovative psychedelic-based therapeutics.

The conference, scheduled for June 16–20, serves as a pivotal platform for leaders in the psychedelic science field to share insights and collaborate on advancing therapeutic options for mental health conditions. Drysdale emphasized the importance of collaborative dialogue in this endeavor, reflecting Cybin's dedication to progressing clinical development and addressing the unmet needs in mental healthcare. Cybin is currently developing CYB003, a proprietary deuterated psilocybin analog for major depressive disorder, and CYB004, a proprietary deuterated DMT molecule for generalized anxiety disorder, among other investigational compounds.

This announcement is significant for the psychedelic and mental health industries as it highlights the growing recognition of psychedelic compounds as potential breakthroughs in treating mental health conditions. Cybin's active role in this space, supported by a network of world-class partners and scientists, positions the company as a leader in the development of safe and effective psychedelic-based therapeutics. The implications of Drysdale's participation in the conference extend beyond Cybin, offering insights into the future of mental health treatment and the potential for psychedelic therapeutics to revolutionize care for millions worldwide.